Valuation: MediciNova, Inc.

Market Cap 65.46M 56.7M 52.85M 48.61M 91.77M 6.22B 92.8M 621M 244M 3.11B 246M 240M 10.32B P/E 2026 *
-5.12x
P/E 2027 * -3.55x
Enterprise Value 65.46M 56.7M 52.85M 48.61M 91.77M 6.22B 92.8M 621M 244M 3.11B 246M 240M 10.32B EV / Sales 2026 *
148x
EV / Sales 2027 * 164x
Free-Float
97.13%
Yield 2026 *
-
Yield 2027 * -
07-15 Medicinova Achieves Target Enrollment in Seanobi-Als Study Evaluating Mn-166 in Als Patients CI
06-08 MediciNova Receives Notice Of Allowance For New Patent Covering Use Of MN-166 In Combination With Anti-PD-1 Immune Checkpoint Inhibitor For Glioblastoma Treatment CI
06-08 MediciNova Granted US Patent Notice of Allowance for Ibudilast Combination to Treat Brain Cancer MT
05-26 MediciNova Announces Completion Of Last Patient Last Visit In The MN-001-NATG-202 Clinical Trial Of MN-001 CI
05-14 MediciNova, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 CI
03-16 HC Wainwright Initiates MediciNova at Buy With $10 Price Target MT
02-20 MediciNova, Inc. Reports Earnings Results for the Full Year Ended December 31, 2025 CI
01-30 MediciNova, Inc. Announces 100 Patients Enrolled in SEANOBI Study Expanded-Access- Program Evaluating MN-166 in ALS Patients CI
12-30 MediciNova Inc enters $50 million equity distribution agreement with Lucid Capital Markets RE
12-18 MediciNova, Inc. Announces Completion of Patient Enrollment Evaluating MN-166 in the Prevention of Chemotherapy-Induced Peripheral Neuropathy CI
12-18 MediciNova Completes Enrollment in a Phase 2 Study of Colorectal Cancer Drug MT
12-08 MediciNova, Inc. Announces Update and Basic Characteristic Randomized Patients' of Phase 2/3 Clinical Trial of MN-166 in ALS (COMBAT-ALS) in ALS Presented at the 36th International Symposium on ALS/MND CI
11-19 MediciNova, Inc. Appoints Dr. Christopher Breder, MD, Phd as Clinical and Regulatory Advisorand to Lead Scientific Advisory Board Upon Its Formation CI
1 day+2.31%
1 week+3.10%
1 month-6.99%
3 months-5.67%
6 months-17.90%
Current year+1.53%
1 week 1.3
Extreme 1.3
1.35
1 month 1.28
Extreme 1.28
1.46
Current year 1.22
Extreme 1.22
1.92
1 year 1.17
Extreme 1.168
1.96
3 years 1.12
Extreme 1.12
2.55
5 years 1.12
Extreme 1.12
4.65
10 years 1.12
Extreme 1.12
14.5
Manager TitleAgeSince
Chief Executive Officer 76 2005-07-31
Director of Finance/CFO 49 2022-06-15
Chief Tech/Sci/R&D Officer 60 2011-08-31
Director TitleAgeSince
Chairman 76 2000-09-25
Director/Board Member 60 2019-07-23
Director/Board Member 69 2004-08-31
Date Insider Type Main position Quantity % Market Cap.
1/16/26 Free

Chief Technology Officer

350,000 0.7122%
1/16/26 Free

Chief Executive Officer

450,000 0.9156%
6/17/25 Free

Director

20,000 0.0408%
Change 5-day change 1-year change 3-year change Capi.($)
+2.31%+3.10%-2.21%-46.15% 65.46M
+4.35%+16.60%+58.11%+95.21% 64.9B
+2.83%-3.48%+24.97%+67.25% 54.05B
+0.91%-0.83%-17.01%-13.43% 23.16B
+0.27%-3.98%-11.28%+350.30% 21.46B
+3.50%+11.22%+32.95%-4.13% 21.25B
+0.75%+1.34%+32.22%-25.25% 17.94B
+9.88%+23.61%+222.87%+385.49% 17.03B
+4.11%+6.44%+21.96%+642.03% 14.99B
+1.25%+2.48%+51.36%+179.72% 14.25B
Average +3.02%+4.31%+41.39%+163.10% 24.91B
Weighted average by Cap. +3.20%+5.59%+42.63%+141.41%

Financials

2026 *2027 *
Net sales 444K 384K 358K 329K 622K 42.17M 629K 4.21M 1.65M 21.1M 1.67M 1.63M 69.88M 400K 346K 323K 297K 561K 38.03M 567K 3.79M 1.49M 19.03M 1.5M 1.47M 63.03M
Net income -13.5M -11.69M -10.9M -10.03M -18.93M -1.28B -19.14M -128M -50.28M -642M -50.71M -49.59M -2.13B -22.14M -19.18M -17.88M -16.44M -31.04M -2.11B -31.38M -210M -82.45M -1.05B -83.16M -81.32M -3.49B
Net Debt - -
Logo MediciNova, Inc.
MediciNova, Inc. is a biopharmaceutical company that is developing therapeutics with a primary focus on neurology, respiratory and liver diseases. The Company's development activities are focused on MN-166 (ibudilast) for neurological and other disorders such as progressive multiple sclerosis (MS), amyotrophic lateral sclerosis (ALS), chemotherapy-induced peripheral neuropathy, degenerative cervical myelopathy, glioblastoma, substance dependence and addiction (methamphetamine dependence, opioid dependence and alcohol dependence), prevention of acute respiratory distress syndrome, and Long COVID, and MN-001 (tipelukast) for fibrotic and other metabolic disorders such as nonalcoholic fatty liver disease and hypertriglyceridemia. Its MN-166 (ibudilast) is a first-in-class, oral, anti-inflammatory and neuroprotective agent. The FDA has granted Fast Track designations to MN-166 (ibudilast) for three separate indications: progressive MS, ALS, and methamphetamine dependence.
Employees
6
Date Price Change Volume
26-08-05 US$1.330 +2.31% 13,758
26-08-04 US$1.300 -2.26% 82,925
26-08-03 US$1.330 0.00% 39,190
26-07-31 US$1.330 -0.75% 8,040
26-07-30 US$1.340 +3.88% 64,069
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
3
Last Close Price
1.330USD
Average target price
9.000USD
Spread / Average Target
+576.69%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. MNOV Stock